---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-071230"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:19:37.930894+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oramed Q3 2022: loss per share $0.18; cash $160M; positive NASH and COVID-19 vaccine data

## Summary
- Cash and investments approximately $160M as of September 30, 2022.
- R&D expenses decreased 12% YoY to $5.3M; basic loss per share improved to $0.18 from $0.21.
- Sales & marketing expense up 169% to $463K; G&A up 60% to $3.1M due to stock-based compensation.
- Reported positive Phase 2 NASH data and positive initial Phase 1 oral COVID-19 vaccine results.
- Phase 3 oral insulin (ORMD-0801) topline data expected in January 2023.

## SEC filing metadata
- accession: 0001213900-22-071230
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390022071230/0001213900-22-071230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390022071230/ea168314-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-071230
- JSON: https://secwatch.observer/filing/0001213900-22-071230.json
- Plain text: https://secwatch.observer/filing/0001213900-22-071230.txt

## Key facts
- Earnings Releases
  ORAMED PHARMACEUTICALS INC. reported the quarter ended September 30, 2022 results: EPS $0.18.
  - Period: the quarter ended September 30, 2022
  - EPS: $0.18
  - Result: reported results
  source text: Basic and diluted loss per share of common stock for the three month period ended September 30, 2022 decreased by 14% to $0.18, compared to $0.21 for the three month period ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1176309/000121390022071230/0001213900-22-071230-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.